Annex
United Kingdom
In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:
- (1)
the following entries are inserted:
Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘007-030-00-3 nitric acid …% [C ≤ 70 %] 231-714-2 7697-37-2. Ox. Liq. 3
Acute Tox. 3
Skin Corr. 1A
H272
H331
H314
GHS03
GHS06
GHS05
Dgr
H272
H331
H314
EUH071 Ox. Liq. 3; H272: C ≥ 65 %
inhalation: ATE = 2,65 mg/L (vapours)
Skin Corr. 1A; H314: C ≥ 20 %
Skin Corr. 1B; H314: 5 % ≤ C < 20 %
B’ ‘014-048-00-5 silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1) 206-991-8 409-21-2
308076-74-6
Carc. 1B H350i GHS08
Dgr
H350i’ ‘014-049-00-0 trimethoxyvinylsilane; trimethoxy(vinyl)silane 220-449-8 2768-02-7 Skin Sens. 1B H317 GHS07
Wng
H317’ ‘014-050-00-6 tris(2-methoxyethoxy)vinylsilane;
6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane
213-934-0 1067-53-4 Repr. 1B H360FD GHS08
Dgr
H360FD’ ‘016-098-00-3 dimethyl disulphide 210-871-0 624-92-0 Flam. Liq. 2
Acute Tox. 3
Acute Tox. 3
STOT SE 3
STOT SE 1
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H225
H331
H301
H336
H370 (upper respiratory tract, inhalation)
H319
H317
H400
H410
GHS02
GHS06
GHS08
GHS09
Dgr
H225
H331
H301
H336
H370 (upper respiratory tract, inhalation)
H319
H317
H410
inhalation: ATE = 5 mg/L (vapours)
oral: ATE = 190 mg/kg bw
M = 1
M = 10’
‘029-024-00-X granulated copper;
[particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm]
231-159-6 7440-50-8 Aquatic Chronic 2 H411 GHS09 H411’ ‘029-025-00-5 bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper;
bis(N-cyclohexyl-diazenium-dioxy)-copper;
[Cu-HDO]
239-703-4 312600-89-8
15627-09-5
Flam. Sol. 1
Acute Tox. 4
STOT RE 2
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H228
H302
H373 (liver)
H318
H400
H410
GHS02
GHS07
GHS08
GHS05
GHS09
Dgr
H228
H302
H373(liver)
H318
H410
oral: ATE = 360 mg/kg bw
M = 1
M = 1’
‘050-031-00-9 dioctyltin dilaurate; [1]
stannane, dioctyl-, bis(coco acyloxy) derivs. [2]
222-883-3 [1] 293-901-5 [2] 3648-18-8 [1] 91648-39-4 [2] Repr. 1B
STOT RE 1
H360D
H372 (immune system)
GHS08
Dgr
H360D
H372 (immune system)’
‘601-092-00-0 dibenzo[def,p]chrysene;
dibenzo[a,l]pyrene
205-886-4 191-30-0 Carc. 1B
Muta. 2
H350
H341
GHS08
Dgr
H350
H341
Carc. 1B; H350: C ≥ 0,001 %’ ‘603-237-00-3 ipconazole (ISO);
(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol
- 125225-28-7
115850-69-6
115937-89-8
Repr. 1B
Acute Tox. 4
STOT RE 2
Aquatic Chronic 1
H360D
H302
H373 (eyes, skin, liver)
H410
GHS08
GHS07
GHS09
Dgr
H360D
H302
H373 (eyes, skin, liver)
H410
oral: ATE = 500 mg/kg bw
M = 100’
‘603-238-00-9 bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme 205-594-7 143-24-8 Repr. 1B H360FD GHS08
Dgr
H360FD’ ‘603-239-00-4 paclobutrazol (ISO);
(2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol
- 76738-62-0 Repr. 2
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H332
H302
H319
H400
H410
GHS08
GHS07
GHS09
Wng
H361d
H332
H302
H319
H410
inhalation: ATE = 3,13 mg/L (dusts or mists)
oral: ATE = 490 mg/kg bw
M = 10
M = 10’
‘603-240-00-X 2,2-bis(bromomethyl)propane-1,3-diol 221-967-7 3296-90-0 Carc. 1B
Muta. 1B
H350
H340
GHS08
Dgr
H350
H340’
‘603-241-00-5 geraniol;
(2E)-3,7-dimethylocta-2,6-dien-1-ol
203-377-1 106-24-1 Skin Sens. 1 H317 GHS07
Wng
H317’ ‘605-041-00-3 2-(4-tert-butylbenzyl)propionaldehyde 201-289-8 80-54-6 Repr. 1B H360Fd GHS08
Dgr
H360Fd’ ‘607-738-00-8 MCPA-thioethyl (ISO);
S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate
246-831-4 25319-90-8 Acute Tox. 4
STOT RE. 2
Aquatic Acute 1 Aquatic Chronic 1
H302
H373 (liver)
H400
H410
GHS07
GHS08
GHS09
Wng
H302
H373 (liver)
H410
oral: ATE = 450 mg/kg bw
M = 10
M = 10’
‘607-740-00-9 diisooctyl phthalate 248-523-5 27554-26-3 Repr. 1B H360FD GHS08
Dgr
H360FD’ ‘607-741-00-4 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone - 951659-40-8 Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H302
H373 (muscle)
H400
H410
GHS07
GHS08
GHS09
Wng
H302
H373 (muscle)
H410
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘607-742-00-X thiencarbazone-methyl (ISO);
methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate
- 317815-83-1 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 1000
M = 1000’
‘607-743-00-5 L-(+)-lactic acid;
(2S)-2-hydroxypropanoic acid
201-196-2 79-33-4 Skin Corr. 1C
Eye Dam. 1
H314
H318
GHS05
Dgr
H314 EUH071’ ‘607-744-00-0 2-methoxyethyl acrylate 221-499-3 3121-61-7 Flam. Liq. 3
Muta. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1
H226
H341
H360FD
H331
H302
H314
H318
H317
GHS02
GHS05
GHS06
GHS08
Dgr
H226
H341
H360FD
H331
H302
H314
H317
EUH071 inhalation: ATE = 2,7 mg/L (vapours)
oral: ATE = 404 mg/kg bw’
‘607-745-00-6 glyoxylic acid …% 206-058-5 298-12-4 Eye Dam. 1
Skin Sens. 1B
H318
H317
GHS05
GHS07
Dgr
H318
H317
B’ ‘607-746-00-1 sodium N-(hydroxymethyl)glycinate;
[formaldehyde released from sodium N-(hydroxymethyl)glycinate]
274-357-8 70161-44-3 Carc. 1B
Muta. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
H350
H341
H332
H302
H335
H315
H319
H317
GHS08
GHS07
Dgr
H350
H341
H332
H302
H335
H315
H319
H317
inhalation: ATE = 3 mg/L (dusts or mists)
oral: ATE = 1100 mg/kg bw
8
9’
‘611-181-00-6 potassium (oxido-NNO-azoxy)cyclohexane;
cyclohexylhydroxydiazene 1-oxide, potassium salt;
[K-HDO]
- 66603-10-9 Flam. Sol. 1
Acute Tox. 3
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Aquatic Chronic 2
H228
H301
H373 (liver)
H315
H318
H411
GHS02
GHS06
GHS08
GHS05
GHS09
Dgr
H228
H301
H373 (liver)
H315
H318
H411
oral: ATE = 136 mg/kg bw’ ‘612-294-00-3 mecetronium etilsulfate;
N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate;
mecetronium ethyl sulphate;
[MES]
221-106-5 3006-10-8 Skin Corr. 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H314
H318
H400
H410
GHS05
GHS09
Dgr
H314
H410
EUH071 M = 100
M = 1000’
‘613-331-00-6 (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;
mefentrifluconazole
- 1417782-03-6 Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 1
M = 1’
‘613-332-00-1 oxathiapiprolin (ISO);
1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone
- 1003318-67-9 Aquatic Chronic 1 H410 GHS09
Wng
H410 M = 1’ ‘613-333-00-7 pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc 236-671-3 13463-41-7 Repr. 1B
Acute Tox. 2
Acute Tox. 3
STOT RE 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H301
H372
H318
H400
H410
GHS08
GHS06
GHS05
GHS09
Dgr
H360D
H330
H301
H372
H318
H410
inhalation: ATE = 0,14 mg/L (dusts or mists)
oral: ATE = 221 mg/kg bw
M = 1000
M = 10’
‘613-334-00-2 flurochloridone (ISO);
3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one
262-661-3 61213-25-0 Repr. 1B
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H360FD
H302
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H360FD
H302
H317
H410
oral: ATE = 500 mg/kg bw
M = 100
M = 100’
‘613-335-00-8 4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT] 264-843-8 64359-81-5 Acute Tox. 2
Acute Tox. 4
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H330
H302
H314
H318
H317
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H302
H314
H317
H410
EUH071 inhalation: ATE = 0,16 mg/L (dusts or mists)
oral: ATE = 567 mg/kg bw
Skin Irrit. 2; H315: 0,025 % ≤ C < 5 %
Eye Irrit. 2; H319: 0,025 % ≤ C < 3 %
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100’
‘613-336-00-3 2-methyl-1,2-benzothiazol-3(2H)-one;
[MBIT]
- 2527-66-4 Acute Tox. 4
Acute Tox. 3
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 2
H312
H301
H314
H318
H317
H400
H411
GHS06
GHS05
GHS09
Dgr
H312
H301
H314
H317
H410
EUH071 dermal: ATE = 1100 mg/kg bw
oral: ATE = 175 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 1’
‘616-228-00-4 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide;
fluxapyroxad
- 907204-31-3 Lact.
Aquatic Acute 1
Aquatic Chronic 1
H362
H400
H410
GHS09
Wng
H362
H410
M = 1
M = 1’
‘616-230-00-5 N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] 213-103-2 924-42-5 Carc. 1B
Muta. 1B
STOT RE 1
H350
H340
H372 (peripheral nervous system)
GHS08
Dgr
H350
H340
H372 (peripheral nervous system)’
‘616-231-00-0 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide;
penflufen
- 494793-67-8 Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H400
H410
GHS08
GHS09
Wng
H351
H410
M = 1
M = 1’
‘616-232-00-6 iprovalicarb (ISO);
isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate
- 140923-17-7 Carc. 2 H351 GHS08
Wng
H351’ ‘616-233-00-1 silthiofam (ISO);
N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide
- 175217-20-6 STOT RE 2
Aquatic Chronic 2
H373
H411
GHS08
GHS09
Wng
H373
H411’
‘650-057-00-6 Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide] 283-644-7 84696-25-3 Aquatic Chronic 3 H412 H412’ - (2)
the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:
Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘007-004-00-1 nitric acid …% [C > 70 %] 231-714-2 7697-37-2 Ox. Liq. 2
Acute Tox. 1
Skin Corr. 1A
H272
H330
H314
GHS03
GHS06
GHS05
Dgr
H272
H330
H314
EUH071 Ox. Liq. 2; H272: C ≥ 99 %
Ox. Liq. 3; H272: 70 % ≤ C < 99 %
B’ ‘014-018-00-1 octamethylcyclotetrasiloxane;
[D4]
209-136-7 556-67-2 Repr. 2
Aquatic Chronic 1
H361f ***
H410
GHS08
GHS09
Wng
H361f ***
H410
M = 10’ ‘015-134-00-5 pirimiphos-methyl (ISO);
O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate
249-528-5 29232-93-7 Acute Tox. 4
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H372 (nervous system)
H400
H410
GHS07
GHS08
GHS09
Dgr
H302
H372 (nervous system)
H410
oral: ATE = 1414 mg/kg bw
M = 1000
M = 1000’
‘015-181-00-1 phosphine 232-260-8 7803-51-2 Flam. Gas 1
Press. Gas
Acute Tox. 1
Skin Corr. 1B
Aquatic Acute 1
H220
H330
H314
H400
GHS02
GHS04
GHS06
GHS05
GHS09
Dgr
H220
H330
H314
H400
inhalation:
ATE = 10 ppmV (gases)
U’ ‘050-021-00-4 dichlorodioctylstannane 222-583-2 3542-36-7 Repr. 1B
Acute Tox. 2
STOT RE 1
Aquatic Chronic 3
H360D
H330
H372 **
H412
GHS08
GHS06
Dgr
H360D
H330
H372 **
H412
Repr. 1B; H360 D: C ≥ 0,03 %
inhalation: ATE = 0,098 mg/L (dusts or mists)’
‘050-027-00-7 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE] 239-622-4 15571-58-1 Repr. 1B
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H372 (immune system)
H400
H410
GHS08
GHS09
Dgr
H360D
H372 (immune system)
H410’
‘082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A
Lact.
Aquatic Acute 1
Aquatic Chronic 1
H360FD
H362
H400
H410
GHS08
GHS09
Dgr
H360FD H362
H410
Repr. 1A; H360D: C ≥ 0,03 %
M = 1
M = 10’
‘603-014-00-0 2-butoxyethanol;
ethylene glycol monobutyl ether
203-905-0 111-76-2 Acute Tox. 4*
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2
H332
H302
H315
H319
GHS07
Wng
H332
H302
H315
H319
oral: ATE = 1200 mg/kg bw’ ‘603-065-00-9 m-bis(2,3-epoxypropoxy)benzene;
resorcinol diglycidyl ether
202-987-5 101-90-6 Carc. 1B
Muta. 2
Acute Tox. 3
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Chronic 3
H350
H341
H311
H302
H315
H319
H317
H412
GHS08
GHS06
Dgr
H350
H341
H311
H302
H315
H319
H317
H412
dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’ ‘607-177-00-9 tribenuron-methyl (ISO);
methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate
401-190-1 101200-48-0 STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H373
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H373
H317
H410
M = 100
M = 100’
‘607-256-00-8 azoxystrobin (ISO);
methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate
- 131860-33-8 Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H331
H400
H410
GHS06
GHS09
Dgr
H331
H410
inhalation:
ATE = 0,7 mg/L (dusts or mists)
M = 10
M = 10’
‘607-314-00-2 ethofumesate (ISO);
(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate
247-525-3 26225-79-6 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 1
M = 1’
‘609-041-00-4 2,4-dinitrophenol 200-087-7 51-28-5 Acute Tox. 3 *
Acute Tox. 3
Acute Tox. 2
STOT RE 1
Aquatic Acute 1
H331
H311
H300
H372
H400
GHS06
GHS08
GHS09
Dgr
H331
H311
H300
H372
H400
dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’ ‘609-064-00-X mesotrione (ISO);
2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione
- 104206-82-8 Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H373 (eyes, nervous system)
H400
H410
GHS08
GHS09
Wng
H361d
H373 (eyes, nervous system)
H410
M = 10
M = 10’
‘613-112-00-5 octhilinone (ISO);
2-octyl-2H-isothiazol-3-one; [OIT]
247-761-7 26530-20-1 Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1 Aquatic Chronic 1
H330
H311
H301
H314
H318
H317
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H311
H301
H314
H317
H410
EUH071 inhalation: ATE = 0,27 mg/L (dusts or mists)
dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100’
‘613-115-00-1 hymexazol (ISO);
3-hydroxy-5-methylisoxazole
233-000-6 10004-44-1 Repr. 2
Acute Tox. 4
Eye Dam. 1
Skin Sens. 1
Aquatic Chronic 2
H361d
H302
H318
H317
H411
GHS08
GHS07
GHS05
GHS09
Dgr
H361d
H302
H318
H317
H411
oral: ATE = 1600 mg/kg bw’ ‘613-125-00-6 hexythiazox (ISO);
trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide
- 78587-05-0 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 1
M = 1’
‘613-202-00-4 pymetrozine (ISO);
(E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one
- 123312-89-0 Carc. 2
Repr. 2
Aquatic Chronic 1
H351
H361fd
H410
GHS08
GHS09
Wng
H351
H361fd
H410
M = 1’ ‘613-259-00-5 imiprothrin (ISO);
reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate
428-790-6 72963-72-5 Carc. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H332
H302
H371 (nervous system; oral, inhalation)
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H332
H302
H371 (nervous system; oral, inhalation)
H410
inhalation: ATE = 1,4 mg/L (dusts or mists)
oral: ATE = 550 mg/kg bw
M = 10
M = 10’
‘616-014-00-0 butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime 202-496-6 96-29-7 Carc. 1B
Acute Tox. 4
Acute Tox. 3
STOT SE 3
STOT SE 1
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1
H350
H312
H301
H336
H370 (upper respiratory tract)
H373 (blood system)
H315
H318
H317
GHS08
GHS06
GHS05
Dgr
H350
H312
H301
H336
H370 (upper respiratory tract)
H373 (blood system)
H315
H318
H317
dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’ ‘617-006-00-X bis(α,α-dimethylbenzyl) peroxide 201-279-3 80-43-3 Org. Perox. F
Repr. 1B
Skin Irrit. 2
Eye Irrit. 2
Aquatic Chronic 2
H242
H360D
H315
H319
H411
GHS02
GHS08
GHS07
GHS09
Dgr
H242
H360D
H315
H319
H411’
- (3)
the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.